ANNX - Annexon Biosciences Market Capitalization-to-Revenue Ratio
Annexon, Inc. (ANNX) possesses significant market influence due to its unique C1q protein therapy for combating neurodegeneration. The price-to-sales ratio demonstrates capitalization dynamics relative to revenue, where represents the latest metric reading. The firm's environmental footprint is minimal and limited to laboratory controls. However, geopolitical instability and sanctions are currently slowing international clinical trials.
Annexon Inc. (ANNX) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization statistics:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Annexon, Inc.|ANNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient Annexon Biosciences Inc.|ANNX - Company Aggregate Debts|Debts to Book Capitalization Annexon Inc.|ANNX - Company Long-Term Debt|Company Short-Term Indebtedness Annexon|Immediate Liquidity Ratio annexonbio.com
- net income and valuation ratios data:
ANNX - Net Income|Net Profit Forecast Annexon, Inc.|ANNX - Price to Earnings Ratio|Price to Future Earnings Ratio Annexon Biosciences|ANNX - PEG Multiple|Company Value to EBITDA Annexon Inc.|ANNX - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Annexon|ANNX - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months annexonbio.com|ANNX - Earnings per share growth in current year|Expected net earnings per share growth next year Annexon, Inc.
- total revenue and sales volume data:
General company analysis:ANNX annexonbio.com
The P/S ratio compares market capitalization to actual revenue, allowing for an assessment of the cost of one dollar of sales without relying on subjective profit estimates. By analyzing the volatility of the P/S ratio, an investor can determine the extent of the premium paid for the potential of Annexon, Inc. (ANNX) in the field of neurology, where business valuation depends directly on the success of clinical trials and the patent protection of new drugs.
Competitors of Annexon, Inc.
biogen.com - Market Cap to Revenue Ratio|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|Axsome Therapeutics Inc - P/S Multiple|Price-to-Revenue Coefficient ACADIA Corp ACAD|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Market Cap to Revenue Catalyst Pharma (CPRX)|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Price-to-Revenue Coefficient Harmony Corp|P/S Multiple BHVN (Biohaven Ltd.)|P/S Multiple amylyx.com AMLX|TRVI - Price-to-Revenue Ratio|PRAX (Praxis Precision Medicines Inc) - Market Cap to Revenue Ratio|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CBLL|Market Cap to Revenue PRTA|Market Cap to Revenue Ratio ALEC (Alector Therapeutics)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Inc - Market Cap to Revenue Ratio|P/S Multiple ACIU (AC Immune Corp)|Voyager Corp (VYGR) - Price to Sales|NMRA: Market Cap to Revenue|SCLX - P/S Multiple|Tevogen Bio (TVGN) - Price-to-Revenue Ratio|Alpha Cognition Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|Price to Sales Inhibikase Pharma IKT|P/S Multiple SAVA|P/S Multiple assertiotx.com (ASRT)|Price-to-Revenue Ratio Coya Therapeutics COYA|VTGN: Market Cap to Revenue Ratio|OVID - Price-to-Revenue Ratio|ABOS (Acumen Pharmaceuticals, Inc) - Market Cap to Revenue Ratio|CRVO: P/S Multiple|Price to Sales Alterity Therapeutics Limited (ATHE)|Market Cap to Revenue CLNN|Market Cap to Revenue Ratio PEPG (PepGen Corp)|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD - Price to Sales|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|GRCE: Market Cap to Revenue Ratio|AIFF: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio KLTO (Klotho Neurosciences Inc)|NRSN: P/S Multiple|RVPH - Price-to-Revenue Coefficient|Price-to-Revenue Ratio MetaVia Inc.|Market Cap to Revenue Ratio NRXS (neuraxis.com)|P/S Multiple HSDT|Market Cap to Revenue passagebio.com PASG|Neuphoria Therapeutics - Market Cap to Revenue|Price-to-Revenue Coefficient Minerva (NERV)|Athira Pharma, Inc. - P/S Multiple|ADXN - P/S Multiple|alzamend.com (ALZN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CYCN|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Market Cap to Revenue Ratio KTTA (Pasithea)|Market Cap to Revenue CRGT (Cortigent, Inc.)|avenuetx.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|CARA: Market Cap to Revenue Ratio|Chromocell Therapeutics Corporation - P/S Multiple|Price to Sales Eliem Therapeutics|ITCI (intracellulartherapies.com) - Market Cap to Revenue|longboardpharma.com (LBPH) - P/S Multiple|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE - Price to Sales|P/S Multiple SNPX (Synaptogenix, Inc.)|P/S Multiple trevena.com TRVN|VIGL - Price-to-Revenue Ratio|WENA (anewmeds.com) - Market Cap to Revenue Ratio|Cerevel (CERE) - Price-to-Revenue Ratio
